Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Kiniksa Pharmaceuticals International, plc
Bear Case (25th pct.)
-83.2% vs price
Base Case (Median)
-76.9% vs price
Bull Case (75th pct.)
-67.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $25.89 | -66.5% | High (40%) |
| PE Comparable | $21.99 | -71.5% | Medium (25%) |
| Graham Number | $12.70 | -83.6% | Medium (40%) |
| EV/EBITDA | $13.67 | -82.3% | Medium (20%) |
| EV/FCF | $49.15 | -36.4% | Medium (20%) |
| Earnings Power Value | $2.38 | -96.9% | Medium (50%) |
Based on 6 out of 7 methods, KNSA appears overvalued at the current price of $77.24. The base case fair value of $17.83 implies 76.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.